Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Guardant Health, Inc.NASDAQ: GH

Net Receivables · Q3 FY2026 · quarter ended Sep 2026

Net receivables rises 61.4% from a year ago

Net receivables stood at $186.55M at the end of Q3 FY2026, up 61.4% from a year earlier and up 29.3% from the prior quarter. Over 3 fiscal years it compounded at +12.3% a year.

Context

  • Net receivables amounted to 9.9% of total assets at the end of Q3 FY2026, up 0.8 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +61.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$186.55M+29.3% QoQ
Last fiscal yearDec 2025
$137.85M+25.0% YoY
Year agoSep 2025
$115.59M+61.4% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+61.4%——
1 year+25.0%——
3-year CAGR+12.3%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
137.85M USD
Year-over-year change
+25.0%
4-year CAGR
+9.0%

Net Receivables vs competitors

How GH compares with its peers on the latest reported figures

  • GH's Sep 2026 net receivables of $186.55M is the 2nd highest of the 10 companies compared; the peer median is $74.89M.
  • Its year-over-year change of +61.4% is the 2nd highest of 10, against a peer median of +18.7%.
  • Net receivables amounts to 9.9% of total assets for GH, versus a peer median of 10.0%.
GH Competitors Peer median
Net Receivables for GH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NTRANatera, Inc.Jun 2026$421.97M +36.5%+6.7%15.9%
GHGuardant Health, Inc.Sep 2026$186.55M +61.4%+12.3%9.9%
NEONeoGenomics, Inc.Jun 2026$175.41M +14.2%+10.0%13.0%
MYGNMyriad Genetics, Inc.Mar 2026$123.8M +2.8%+4.3%18.4%
FLGTFulgent Genetics, Inc.Mar 2026$75.74M -5.8%+6.8%6.5%
BLLNBillionToOne, Inc.Jun 2026$74.89M +146.1%—10.3%
CSTLCastle Biosciences, Inc.Mar 2026$42.26M -25.0%+22.7%7.7%
GRALGRAIL, Inc.Jun 2026$19.76M +20.6%-0.6%0.7%
PSNLPersonalis, Inc.Mar 2026$13.02M +18.7%-0.9%4.0%
BDSXBiodesix, Inc.Mar 2026$9.5M +24.4%+21.3%10.0%
Peer median (excluding GH) $74.89M+18.7%+6.8%10.0%

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents492.2M141.65M1.13B525.54M378.2M
Short-term Investments440.55M869.58M35.1M314.44M823.4M
Net Receivables97.65M97.26M88.78M110.25M137.85M
Inventory30.67M51.6M61.95M71.08M85.88M
Other Current Assets031.51M27.74M33.8M40.72M
Total Current Assets1.11B1.19B1.35B1.06B1.47B
Property, Plant & Equipment (Net)313.9M341.92M302.71M279.08M304.76M
Goodwill3.29M3.29M3.29M3.29M77.26M
Intangible Assets14.21M11.73M8.98M6.76M25.92M
Long-term Investments698.03M0000
Tax Assets00000
Other Non-current Assets60.94M61.45M124.33M141.37M139.67M
Total Non-current Assets1.09B418.39M439.32M430.5M547.61M
Total Assets2.2B1.61B1.79B1.49B2.01B
Account Payables38.52M68.91M51.74M38.55M54.44M
Short-term Debt00000
Tax Payables4.22M0000
Deferred Revenue11.33M17.4M17.97M35.47M50.75M
Other Current Liabilities120.5M55.79M72.74M83.22M119.65M
Total Current Liabilities194.69M193.22M205.92M225.58M302.73M
Long-term Debt1.13B1.14B1.14B1.14B1.5B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities3.93M9.18M96.01M92.83M127.77M
Total Non-current Liabilities1.36B1.36B1.42B1.4B1.81B
Total Liabilities1.56B1.55B1.63B1.63B2.11B
Common Stock1K1K1K1K1K
Retained Earnings(1.01B)(1.66B)(2.14B)(2.58B)(2.99B)
Accumulated OCI(4.76M)(19.52M)(3.68M)(5.2M)(4.85M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity645.01M60.18M158.68M(139.65M)(99.31M)
Total Debt1.37B1.37B1.35B1.34B1.71B
Net Debt881.53M1.23B220.23M810.51M1.33B

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.